The editors of Optimization in Drug Discovery Process: In Vitro Methods have assembled an international panel of 49 contributors from pharmaceutical and biotechnology companies, academic and government institutions, and a few commercial technology and reagents providers. Their combined expertise spans pharmaceutical sciences, molecular and genetic toxicology, drug metabolism, safety assessment, drug metabolism and pharmacokinetics (DMPK), microbiology and immunology, enzymology, physical chemistry, and chemical biology, resulting in 25 monographs covering the current best practices, tools, technologies, and assays currently used in the preclinical assessment of potential liabilities of drug candidates before their advancement into clinical trials.
In the preface, editors Yan and Caldwell state that a significant number of drug candidates fail in the later stages of clinical development for reasons of poor absorption, distribution, metabolism, and excretion (ADME), and toxicity (tox) issues. The purpose of lead optimization is to uncover and correct these defects, thus lowering drug candidate failures in development and reducing the cost and time to develop therapeutic drugs. Research tools must be made available in drug discovery to rapidly screen for compounds with favorable drug-like properties. This compilation of the detailed experimental protocols necessary for setting up a variety of assays to evaluate physiochemical properties, adsorption, plasma binding, metabolism, drug interactions, and toxicity is a timely and pertinent contribution to the drug discovery literature.
The preface by Yan and Caldwell does an excellent job of providing the reader with the rationale and purpose of this excellent compilation. They lay out the contents of the chapters: what druglike parameter is being measured, the preferred "gold-standard" method for obtaining predictive values, and the context and relationship of the parameter to the profile of a successful drug. The flow and organization of the individual chapters parallel the typical flowchart of assessments for ADME/tox: 1) calculation of fundamental physical properties that affect drug absorption, permeability, and distribution; 2) passive and active adsorption properties, first-pass metabolism, and drug efflux via transporters; 3) protein binding affecting distribution; 4) phase I and II metabolism, inhibition, and induction of CYP enzymes that affect clearance, excretion, and drug-drug interactions; and 5) genotoxicity measurements for DNA damage via CYP-mediated DNA adducts assays, gene reporter systems, or chemical mutagenic potential. In addition to these more "classic" ADME/tox assessments, there are final chapters covering the 1) more recently required HERG channels assessment for QT prolongation, 2) assessment of potential bioactivation to electrophilic intermediates by conjugation to thiols, and 3) assessment of the known reactivity and subsequent toxicity of acyl glucuronide drug metabolites that result from glucuroconjugation of free carboxylic acid compounds, which have led to some market withdrawals.
The format of every chapter is useful to both the neophyte and experienced drug discovery practitioner in providing a good general review of the subject, specific citations of past examples of use, and the critical path decisions pursuant to the study. The neophyte benefits from the breadth, scope, and context of current best practices in 1 authoritative source. Experienced discovery practitioners will recognize literature examples and useful parameter drug correlations, have a ready review of the breadth and scope of the best practices, and use the detailed protocols as a basis for setting up or benchmarking his or her in-house assays. These detailed protocols extensively cover reagents, cell lines, optimal experimental conditions, practical hints and caveats, preferred data reduction methods (and in some cases, useful templates), and guidelines for normal expected values, which aid the neophyte in the interpretation of data and validation of experiments. A particular strength of the monographs is the critical assessment of the limitations and scope of what each of these assays purports to measure and how the measurement should be used and interpreted.
Having an extensive review of the variety of metabolic liability assessments comprising 8 of the 25 chapters was most useful for comparative purposes and drives home the importance of metabolic stability of drugs for clearance, drug-drug interactions through competition and induction of metabolic enzymes, toxicity, and complications of metabolites to all of these. The subtleties of metabolic profiling from liver microsomes, hepatocytes, hepatic S9 fractions, and recombinant cytochrome P450 enzymes are exhaustively detailed in these chapters. For the neophyte, the identities, differences, and limitations of each of these assays will bring understanding and order to the seemingly chaotic and arbitrary plethora of assays that are used to justify advancement of 1 candidate drug over another.
Chapter 11, on in vitro drug metabolism profiling, was particularly useful in providing several illustrative examples of the identification and assignment of metabolites of actual compounds in development by mass spectrometric analysis such as atmospheric pressure ionization-mass spectrometry (API-MS) and API-MS/ MS. Chemical structures of metabolites and their mass spectrometric assignment, a detailed metabolic pathway derived from such analysis, actual API-MS, and an API-MS/MS spectra with the chemical fragmentation structural map serve to clarify this elegant and definitive methodology.
Chapter 5, on the use of brain microvessel endothelial cells to assess the blood-brain barrier permeability of central nervous system candidate drugs, was very enlightening, as this reviewer was unaware of this system. It provides a great complement to the better known systems for assessing intestinal drug absorption and metabolism such as Caco-2 cell (Chapter 2) monolayers, PAMPA (Chapter 3) screens, and perfused rat intestinal models (Chapter 4). Chapters 1 and 9, which detail the more fundamental properties of compounds obtained by elegant quantitative analytical chemical measurement methodologies, were very well written to guide more biologically inclined practitioners in the rigorous mathematics and data reduction commensurate with these methodologies.
One significant omission for toxicological assessments is the micronuclei assay and the imaging advances that have allowed this assay to be rendered in higher throughput fashion.
In summary, this practical, concise, and detailed compilation will be a worthwhile contribution to the screening literature. It will be a much referred-to authoritative "how-to" laboratory manual and resource for pharmaceutical science students, entry-level practitioners, technical staff, managers, experienced practitioners, educators, and researchers.
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